Literature DB >> 9059962

The effects of ammonia and portal-systemic shunting on brain metabolism, neurotransmission and intracranial hypertension in hyperammonaemia-induced encephalopathy.

B A Vogels1, B van Steynen, M A Maas, G G Jörning, R A Chamuleau.   

Abstract

BACKGROUND/AIMS: The pathogenetic factors contributing to encephalopathy in portacaval shunted rats with hyperammonaemia were studied.
METHODS: Hyperammonaemia was induced by ammonium-acetate infusions in portacaval shunted rats (2.8 mmol.kg bw-1.h-1; AI-portacaval shunted rats) and in sham-portacaval shunted rats (6.5 mmol.kg bw-1.h-1; AI-NORM rats). Severity of encephalopathy was quantified by clinical grading and EEG spectral analysis. Changes in brain metabolites were assessed by amino acid analysis of brain cortex homogenates, whereas changes in amino acids with neurotransmitter activity were assessed in cerebrospinal fluid; brain water content was measured by subtracting dry from wet brain weights and intracranial pressure was measured by a pressure transducer connected to a cisterna magna cannula.
RESULTS: Although similar increased blood and brain ammonia concentrations were obtained in both experimental groups, only AI-portacaval shunted rats developed encephalopathy, associated with a significant increase in intracranial pressure. Other significant differences were: higher concentrations of brain glutamine and aromatic amino acids, higher concentrations of cerebrospinal fluid glutamine, aromatic amino acids, glutamate and aspartate in AI-portacaval shunted rats than in AI-NORM rats.
CONCLUSIONS: These results indicate that hyperammonaemia alone dose not induce encephalopathy, whereas portal-systemic shunting adds an essential contribution to the pathogenesis of encephalopathy. It is hypothesised that the larger increase in brain glutamine in AI-portacaval shunted rats than in AI-NORM rats is responsible for increased brain concentrations of aromatic amino acids, for cell swelling and for extracellular release of glutamate and aspartate. This might promote encephalopathy. If cell swelling is not restricted, intracranial hypertension will develop.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9059962     DOI: 10.1016/s0168-8278(97)80057-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

1.  Hyperammonemia and chronic hepatic encephalopathy: an in vivo PMRS study of the rat brain.

Authors:  D Astore; C A Boicelli
Journal:  MAGMA       Date:  2000-07       Impact factor: 2.310

2.  A large spontaneous intrahepatic portosystemic shunt in a cirrhotic patient.

Authors:  Xingshun Qi; Chun Ye; Yue Hou; Xiaozhong Guo
Journal:  Intractable Rare Dis Res       Date:  2016-02

3.  Neuroprotective effects of guanosine administration on behavioral, brain activity, neurochemical and redox parameters in a rat model of chronic hepatic encephalopathy.

Authors:  L G Paniz; M E Calcagnotto; P Pandolfo; D G Machado; G F Santos; G Hansel; R F Almeida; R S Bruch; L M Brum; F V Torres; A M de Assis; E P Rico; D O Souza
Journal:  Metab Brain Dis       Date:  2014-05-01       Impact factor: 3.584

4.  Effect of glutamine synthesis inhibition with methionine sulfoximine on the nitric oxide-cyclic GMP pathway in the rat striatum treated acutely with ammonia: a microdialysis study.

Authors:  Wojciech Hilgier; Michal Wegrzynowicz; Michal Maczewski; Andrzej Beresewicz; Simo S Oja; Pirjo Saransaari; Jan Albrecht
Journal:  Neurochem Res       Date:  2007-08-29       Impact factor: 3.996

5.  Rifaximin, but not growth factor 1, reduces brain edema in cirrhotic rats.

Authors:  Gemma Odena; Mireia Miquel; Anna Serafín; Amparo Galan; Rosa Morillas; Ramon Planas; Ramon Bartolí
Journal:  World J Gastroenterol       Date:  2012-05-07       Impact factor: 5.742

6.  Pressure suppresses hepatocellular glycogen synthesis through activating the p53/Pten pathway.

Authors:  Junwei Shen; Yunchen Sun; Si Shen; Xu Luo; Jie Chen; Liang Zhu
Journal:  Mol Med Rep       Date:  2019-04-19       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.